Information Provided By:
Fly News Breaks for October 29, 2015
ICPT
Oct 29, 2015 | 07:57 EDT
Citi analyst Joel Beatty lowered his price target for Intercept Pharmaceuticals to $340 yesterday after results from the Phase 2 NASH trial of OCA in Japan did not show a clear trend in fibrosis improvement. The analyst maintains a 65% probability of success for OCA in NASH but now sees see higher risk around success of the lower 10mg dose in REGENERATE. He keeps a Buy rating on Intercept.
News For ICPT From the Last 2 Days
There are no results for your query ICPT
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.